{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:39:17Z","timestamp":1792402757824,"version":"4.4.0"},"reference-count":49,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T00:00:00Z","timestamp":1327017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    urkitt lymphoma\/leukaemia is the most common (40%) form of non\u2010\n                    <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                    odgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated)\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    urkitt lymphoma\/leukaemia in children and adolescents three decades ago had a 5\u2010year event\u2010free survival (\n                    <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>\n                    ) of &lt;40%, and required combination chemotherapy and radiation therapy over a 1\u20132\u00a0year period. Currently, the prognosis for the same advanced stage has a 5\u2010year\n                    <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>\n                    of 85\u201390% with &lt;6\u00a0months of chemotherapy only. Radiation therapy has been eliminated for children and adolescents with\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    urkitt lymphoma\/leukaemia except in emergencies, such as superior vena cava syndrome and acute neurological impairment or in patients with relapse\/progression. Current risk factors in the prognosis of childhood and adolescent\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    urkitt lymphoma\/leukaemia include: lactate dehydrogenase level\u00a0\u2265\u00a02\u00d7 the upper normal limit at diagnosis, bone marrow and central nervous system involvement, poor response to cyclophosphamide, vincristine and prednisone reduction therapy and poor risk cytogenetics. New and novel therapeutic approaches include monoclonal antibody (anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    20) therapy, targeted cellular immune therapy and small molecule inhibitors. Future strategies should include improved staging and risk classification, reduction of cytotoxic chemotherapy, the investigation of targeted therapy, an increased understanding of the underlying biology of\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    urkitt lymphoma\/leukaemia, strategies for prevention and approaches to reduce acute and chronic toxicities.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.09024.x","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T04:42:51Z","timestamp":1327034571000},"page":"730-743","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Risk factors and treatment of childhood and adolescent\n                    <scp>B<\/scp>\n                    urkitt lymphoma\/leukaemia"],"prefix":"10.1111","volume":"156","author":[{"given":"Rodney R.","family":"Miles","sequence":"first","affiliation":[{"name":"Department of Pathology University of Utah Salt Lake City UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Pediatrics NewYork\u2010Presbyterian Morgan Stanley Children's Hospital Columbia University New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy New York Medical College Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"e_1_2_21_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1024"},{"key":"e_1_2_21_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"e_1_2_21_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.18004619704"},{"key":"e_1_2_21_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_21_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402402"},{"key":"e_1_2_21_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_21_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_2_21_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.9536"},{"key":"e_1_2_21_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369"},{"key":"e_1_2_21_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07943.x"},{"key":"e_1_2_21_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_21_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_21_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605037"},{"key":"e_1_2_21_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-384-8_17"},{"key":"e_1_2_21_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7"},{"key":"e_1_2_21_18_1","first-page":"278","article-title":"Excellent outcome of CNS\u2010positive pediatric Burkitt lymphoma and other mature B\u2010NHL treated with cobmined chemo\u2010immunotherapy (rituximab + FAB Group C) without CNS radiation: a Children's Oncology Group report","volume":"22","author":"Frazer J.K.","year":"2011","journal-title":"Annals of Oncology"},{"key":"e_1_2_21_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"e_1_2_21_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_21_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_21_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2005.12.005"},{"key":"e_1_2_21_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2352"},{"key":"e_1_2_21_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03552"},{"key":"e_1_2_21_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07393.x"},{"key":"e_1_2_21_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_21_27_1","volume-title":"Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_21_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136465"},{"key":"e_1_2_21_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200403000-00006"},{"key":"e_1_2_21_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_21_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_21_32_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_21_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8161"},{"key":"e_1_2_21_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07967.x"},{"key":"e_1_2_21_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22089"},{"key":"e_1_2_21_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1219"},{"key":"e_1_2_21_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_21_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_21_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_21_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301556"},{"key":"e_1_2_21_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_2_21_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13071"},{"key":"e_1_2_21_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08883.x"},{"key":"e_1_2_21_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.026831"},{"key":"e_1_2_21_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08681.x"},{"key":"e_1_2_21_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1226"},{"key":"e_1_2_21_47_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_21_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007089"},{"key":"e_1_2_21_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-0755-7.00490-5"},{"key":"e_1_2_21_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.09024.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.09024.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:06:11Z","timestamp":1694592371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.09024.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,20]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1365-2141.2011.09024.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.09024.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,20]]},"assertion":[{"value":"2011-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}